ACCEPTED MANUSCRIPT
[1] Z. Lu, J. B. Napolitano, A. Theberge, A. Ali, M. L. Hammond, E. Tan, X. Tong, S. S. Xu, M. J. Latham, L. B. Peterson, M. S.
Anderson, S. S. Eveland, Q. Guo, S. A. Hyland, D. P. Milot, Y. Chen, C. P. Sparrow, S. D. Wright,P. J. Sinclair, Design of a
novel class of biphenyl CETP inhibitors, Bioorg. Med. Chem. Lett. 20 (2010) 7469-72.
[2] E. S. Ford,S. Capewell, Coronary heart disease mortality among young adults in the U.S. from 1980 through 2002: concealed
leveling of mortality rates, J. Am. Coll. Cardiol. 50 (2007) 2128-32.
[3] R. Kones,U. Rumana, Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs, Drugs 75 (2015)
1201-28.
[4] R. Kones,U. Rumana, Current Treatment of Dyslipidemia: A New Paradigm for Statin Drug Use and the Need for Additional
Therapies, Drugs 75 (2015) 1187-99.
[5] F. Barzi, A. Patel, M. Woodward, C. M. Lawes, T. Ohkubo, D. Gu, T. H. Lam, H. Ueshima,C. Asia Pacific Cohort Studies, A
comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region, Ann. Epidemiol. 15 (2005) 405-
13.
[6] S. M. Grundy, J. I. Cleeman, C. N. Merz, H. B. Brewer, Jr., L. T. Clark, D. B. Hunninghake, R. C. Pasternak, S. C. Smith, Jr., N.
J. Stone, L. National Heart, I. Blood, F. American College of Cardiology,A. American Heart, Implications of recent clinical
trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation 110 (2004) 227-39.
[7] D. J. Gordon, J. L. Probstfield, R. J. Garrison, J. D. Neaton, W. P. Castelli, J. D. Knoke, D. R. Jacobs, Jr., S. Bangdiwala,H. A.
Tyroler, High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies, Circulation 79
(1989) 8-15.
[8] B. Paigen, B. Y. Ishida, J. Verstuyft, R. B. Winters,D. Albee, Atherosclerosis susceptibility differences among progenitors of
recombinant inbred strains of mice, Arteriosclerosis 10 (1990) 316-23.
[9] M. D. Carroll, D. A. Lacher, P. D. Sorlie, J. I. Cleeman, D. J. Gordon, M. Wolz, S. M. Grundy,C. L. Johnson, Trends in serum
lipids and lipoproteins of adults, 1960-2002, JAMA 294 (2005) 1773-81.
[10] M. C. Brouwers,C. D. Stehouwer, Niacin in cardiovascular patients receiving statins, N. Engl. J. Med. 366 (2012) 1255; author
reply 1255-6.
[11] H. T. C. Group, M. J. Landray, R. Haynes, J. C. Hopewell, S. Parish, T. Aung, J. Tomson, K. Wallendszus, M. Craig, L. Jiang,
R. Collins,J. Armitage, Effects of extended-release niacin with laropiprant in high-risk patients, N. Engl. J. Med. 371 (2014)
203-12.
[12] T. J. Anderson, W. E. Boden, P. Desvigne-Nickens, J. L. Fleg, M. L. Kashyap, R. McBride, J. L. Probstfield,A.-H. Investigators,
Safety profile of extended-release niacin in the AIM-HIGH trial, N. Engl. J. Med. 371 (2014) 288-90.
[13] J. A. Hunt,Z. Lu, Cholesteryl ester transfer protein (CETP) inhibitors, Curr. Top. Med. Chem. 9 (2009) 419-27.
[14] S. J. Nicholls, E. M. Tuzcu, I. Sipahi, A. W. Grasso, P. Schoenhagen, T. Hu, K. Wolski, T. Crowe, M. Y. Desai, S. L. Hazen, S.
R. Kapadia,S. E. Nissen, Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis, JAMA 297
(2007) 499-508.
[15] F. Matsuura, N. Wang, W. Chen, X. C. Jiang,A. R. Tall, HDL from CETP-deficient subjects shows enhanced ability to promote
cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway, J. Clin. Invest. 116 (2006) 1435-42.
[16] Y. C. Ha,P. J. Barter, Differences in plasma cholesteryl ester transfer activity in sixteen vertebrate species, Comp. Biochem.
Physiol. B Biochem. Mol. Biol. 71 (1982) 265-9.
[17] K. R. Marotti, C. K. Castle, T. P. Boyle, A. H. Lin, R. W. Murray,G. W. Melchior, Severe atherosclerosis in transgenic mice
expressing simian cholesteryl ester transfer protein, Nature 364 (1993) 73-5.
[18] J. D. Curb, R. D. Abbott, B. L. Rodriguez, K. Masaki, R. Chen, D. S. Sharp,A. R. Tall, A prospective study of HDL-C and
cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly, J. Lipid Res. 45 (2004)
948-53.
[19] B. A. Kingwell, M. J. Chapman, A. Kontush,N. E. Miller, HDL-targeted therapies: progress, failures and future, Nat. Rev. Drug
Discov. 13 (2014) 445-64.
[20] P. J. Barter, M. Caulfield, M. Eriksson, S. M. Grundy, J. J. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J. C. Tardif, D.
D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, B. Brewer,I. Investigators, Effects of torcetrapib in
patients at high risk for coronary events, N. Engl. J. Med. 357 (2007) 2109-22.
[21] D. S. Robinson,H. H. Kariyawasam, Mepolizumab for eosinophilic severe asthma: recent studies, Expert. Opin. Biol. Ther. 15
(2015) 909-14.
[22] S. Stiles, Lilly Pulls Plug on Its CETP Inhibitor Evacetrapib, Medscape (October 12, 2015).
[23] S. Jager, H. Trojan, T. Kopp, M. N. Laszczyk,A. Scheffler, Pentacyclic triterpene distribution in various plants - rich sources for
a new group of multi-potent plant extracts, Molecules 14 (2009) 2016-31.
[24] Y. Muto, M. Ninomiya,H. Fujiki, Present status of research on cancer chemoprevention in Japan, Jpn. J. Clin. Oncol. 20 (1990)
219-24.
[25] P. Dzubak, M. Hajduch, D. Vydra, A. Hustova, M. Kvasnica, D. Biedermann, L. Markova, M. Urban,J. Sarek, Pharmacological
activities of natural triterpenoids and their therapeutic implications, Nat. Prod. Rep. 23 (2006) 394-411.
[26] H. Sheng,H. Sun, Synthesis, biology and clinical significance of pentacyclic triterpenes: a multi-target approach to prevention
and treatment of metabolic and vascular diseases, Nat. Prod. Rep. 28 (2011) 543-93.